Tuesday, October 10, 2017| , ASDS,

DermWireTV: Updates from ASDS 2017

From microneedling to skin redraping to body contouring, the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) brings cosmetic and surgical dermatology into focus. With an emphasis on the state of the art in dermatologic procedures, the annual meeting of the ASDS gathered hundreds of specialists in Chicago. As in years past, the gathering included representation of other core cosmetic specialties in a spirit of collaboration. (565 Views)

Watch Video

Thursday, September 21, 2017| , Allergan , , European Academy of Dermatology,

eRelevance Uncovers Marketing Truths, EADV Data, Primetime for Botox

The State of Aesthetic Healthcare Marketing 2017 from eRelevance shows that nearly 60 percent of aesthetic physicians say they either don’t see results from their marketing initiatives or aren’t able to measure results. Data presented at the annual meeting of the European Academy of Dermatology and Venereology support the role of Regeneron and Sanofi’s Dupixent, Lilly’s experimental JAK inhibitor Baricitinib, Novartis’ Cosentyx, Janssen’s Tremfya, and a new low-level blue and red light therapy face mask for acne vulgaris. Athlete and sports analyst Deion Sanders recently turned 50, and he's talking about the Botox Cosmetic treatment he received for the milestone. (1200 Views)

Watch Video

Thursday, August 24, 2017| , La Roche-Posay, , Neutrogena, , U.S. Food and Drug Administration (FDA),

DermWireTV: UV Safety Goes Viral, Salon Exposures Exposed

The Skin Checker viral video from La Roche Posay coincides with the launch of La Roche Posay’s new Anthelios Dermo-KIDS Sunscreen SPF 60. The company has also reported data showing the benefits of its wearable My UV Patch sensor and associated kid-friendly mobile app. Neutrogena’s MimicMommy MOVEment has the company teamed up YouTube stars the Holderness Family to encourage sun protection. The Environmental Working Group and Women’s Voices for the Earth are suing the FDA, saying that the agency isn’t doing enough to protect consumers from unsafe levels of formaldehyde in hair straighteners. An unrelated recent publication shows that women with skin of color have higher levels of beauty-product related chemicals in their bodies compared to white women. (1357 Views)

Watch Video

Thursday, August 03, 2017

DermWireTV: Summer AAD NYC Updates; Modernizing Medicine Grows

As in years past, the summer meeting of the AAD has focused attention on optimal uses for both existing and emerging therapies in the dermatology clinic, including, PRP. Dr. Nicole Rogers assessed the role of PRP for hair loss. Diane Berson, MD discusses acne, Adam Friedman, MD addresses the microbiome, Elma Baron, MD talks about phototherapy for psoriasis, and Nada Elbuluk, MD highlights investigational treatments for melasma. Also, Modernizing Medicine announces plans to more than double its staff. (1834 Views)

Watch Video

Wednesday, July 26, 2017| , Obagi, , Valeant NJ,

DermWireTV: Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired

Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech’s Tremfya (guselkumab), the first and only approved biologic therapy that selectively blocks only IL-23. The DERM 2017 NP/PA CME Conference has concluded in Las Vegas. Valeant is selling its Obagi Medical Products division for $190 million in cash to a Chinese investment group. (1491 Views)

Watch Video

Thursday, June 22, 2017| , Revance Therapeutics, Inc, , Atopic Derm, , Atopic Dermatitis , , Tattoo ,

DermWireTV: Revance Data, AD Updates, FDA Actions

A US District Court judge blocks Stratus Pharmaceuticals of Miami and Sonar Products of Carlstadt, NJ from selling substandard dermatological products. Newly identified mutations in a gene called CARD11 may lead to atopic dermatitis. Surprising new evidence suggests atopic dermatitis is associated with somewhat reduced risk of stroke, hypertension, diabetes, and heart attack. Results of Phase 2 BELMONT study: 40U dose of Revanche's RT002 has a significantly longer duration of response,compared to onabotulinumtoxinA. And FDA warns on black henna tattoos. (2296 Views)

Watch Video

Wednesday, June 07, 2017

DermWireTV: Derm Surgeries Top 10M; VCS Kicks Off; Tildrakizumab with FDA

Dermatologic surgical procedures continue to increase in popularity. Dermatologic surgeons performed nearly 10.5 million medically necessary and cosmetic procedures in 2016—up five percent from 2015 and up 31 percent since 2012. Results are presented in the 2016 American Society for Dermatologic Surgery (ASDS)Survey on Dermatologic Procedures. Vegas Cosmetic Surgery is underway at the Bellagio. The multispecialty program educates dermatologists, plastic surgeons, facial plastic surgeons, and oculoplastic surgeons. Following FDA clearance, the Clarify Medical Phototherapy System at-home UVB phototherapy system will be available to patients with chronic skin diseases in November. (1434 Views)

Watch Video

Thursday, May 25, 2017| , American Academy of Dermatology, , Johnson & Johnson,

DermWireTV: Sunscreen Ratings, Long Live Skin Launches, SCALE Highlights

Consumer Reports says that one-third of sunscreens tested in its latest evaluation provided less than half of the SPF protection touted on the label. For its part, the American Academy of Dermatology is reminding patients that sunscreen ingredients are safe. The Environmental Working Group continues to caution consumers about “worrisome” ingredients in sunscreen formulations. CVS is launching the Long Live Skin campaign with a focus on sun safety during Skin Cancer Awareness month. In conjunction, Johnson & Johnson will donate $1 to the American Cancer Society for every Neutrogena or Aveeno product with SPF 15 or higher purchased from June 18-24. The Music City SCALE meeting has completed its 12th annual gathering in Nashville. People who smile are actually perceived as older than those with a deadpan or surprised expression, according to a study published in Psychonomic Bulletin and Review. (2602 Views)

Watch Video

Wednesday, May 03, 2017

DermWireTV: Skin Cancer Prevention, Mohs Data, Allergan Closes on Zeltiq

It's Skin Cancer Awareness Month. Joel L. Cohen, MD and Shadi Kourosh, MD share tips on patient education and skin protection. Plus, new data set the stage for developing best practices for Mohs micrographic surgery. Wendy Lewis offers tips for digital marketing success. Plus, Allergan closes the deal on Zeltiq. (3461 Views)

Watch Video

Tuesday, April 25, 2017

DermWireTV: AAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing

It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JAAD shows. In the Phase 3 ALCANZA trial, Seattle Genetics’ and Takeda’s ADCETRIS was associated with a statistically significant improvement in the objective response rate in subjects with CTCL. Valeant Pharmaceuticals’ SILIQ injection of brodalumab will be priced at $3,500 per month, making it the least expensive injectable biologic psoriasis treatment currently on the market, the company says. (2017 Views)

Watch Video

Thursday, April 13, 2017

DermWireTV: Rhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale

Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash. Hollywood has a “tendency to depict skin disease in an evil context,” authors of a new JAMA Dermatology analysis of famous movie heroes and villains conclude. PLUS: An update on anti-MOC efforts, with comment from H.L. Greenberg, MD. (2507 Views)

Watch Video

Wednesday, March 29, 2017

DermWireTV: Dupixent, Juvéderm Vollure XC, Bavencio Approvals

The FDA has approved Regeneron’s injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan’s Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months. EMD Serono’s Bavencio (avelumab) has received FDA fast-track approval for treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma. And research shows no significant difference in outcomes when topical or oral antibiotics are added to standard eczema treatment with steroid creams and emollients. (3219 Views)

Watch Video
Load More